EE411 Budget Impact Analysis of Subcutaneous Infliximab (CT-P13 SC) for Treating Inflammatory Bowel Disease in Saudi Arabia: Analysis from Payer Perspective

Abstract

Authors

H Abumansour N Alkhatib A Almutairi M Almadi S Halloush Y Alruthia O Rashdan S. Al-Shatnawi N Azzam M Mosli A Badawoud M Al Yami A Alhossan I Alharbi